{"entity":{"id":"orlucent","kind":"company","name":"Orlucent","aka":["Orlucent, Inc.","ORLUCENT, INC."],"tldr":"Orlucent is a California company making a handheld imaging system that uses a fluorescent agent on the skin to judge whether a mole is turning into melanoma. It is in clinical trials and not yet approved for diagnosis in the United States.","summary":"Orlucent, Inc., of Los Gatos, California, has developed a handheld fluorescent molecular imaging system, the Orlucent System, to assess the likelihood of a mole's transition to melanoma; the website states that it is in clinical trials and for research use only in the United States. In fiscal year 2026 NCI awarded it USD 1,556,529 under SBIR Direct-to-Phase II grant 1R44CA306680-01A1 to develop manufacturing controls for ORL1, the fluorescent imaging agent used by its skin fluorescent imaging system; the award abstract reports 100 per cent sensitivity and 95.7 per cent specificity in distinguishing melanomas from non-melanomas in preliminary studies.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://orlucent.com/"},{"label":"NIH RePORTER: award 1R44CA306680-01A1","url":"https://reporter.nih.gov/project-details/11410547"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":["imaging","early-detection","diagnostics"],"technologies":["optical-imaging"],"targets":[],"drugs":["orlucent-system"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The sensitivity and specificity figures are from preliminary studies reported in the company's award abstract, not a published trial. Founding year not stated. Read on orlucent.com and NIH RePORTER on 4 November 2026."],"hq":"Los Gatos, CA","country":"US","companyType":"imaging","website":"https://orlucent.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":1556529,"source":"https://reporter.nih.gov/project-details/11410547","note":"NCI SBIR Phase II (R44) award 1R44CA306680-01A1: Development of Manufacturing Controls for ORL1: A Fluorescent Imaging Agent for In Vivo Molecular Imaging of Melanomas"}]},"route":"/companies/orlucent/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"},{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"}],"technology":[{"id":"optical-imaging","kind":"technology","name":"Optical & fluorescence imaging","route":"/technologies/optical-imaging/"}],"drug":[{"id":"orlucent-system","kind":"drug","name":"Orlucent System","route":"/drugs/orlucent-system/"}]}}